Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731042 | 0.86 | MAPT (0.47) | KDM4ELMNAALDH1A1HPGDKMT2A | |
| SCHEMBL735233 | 0.85 | KDM4E (0.51) | KDM4ELMNARECQLALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL730878 | 0.79 | HSD17B10 (0.40) | KDM4ELMNAALDH1A1SMN1; SMN2HSD17B10 | |
| Hydrochloric Acid SCHEMBL728945 | 0.79 | HSD17B10 (0.40) | KDM4ELMNAALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL728888 | 0.73 | ADORA3 (0.41) | ALDH1A1HSD17B10HPGDKMT2AADORA3 | |
| SCHEMBL729439 | 0.72 | ADORA3 (0.40) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL728993 | 0.71 | ADORA3 (0.44) | KDM4EALDH1A1HSD17B10HPGDKMT2A | |
| SCHEMBL1895662 | 0.70 | ALDH1A1 (0.44) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL31487317 | 0.69 | KDM4E (0.68) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL1165573 | 0.69 | KDM4E (0.68) | KDM4ELMNAALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138173-B2 | Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090069299-A1 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069299-A1 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods | IL4, IL2, IL5 | KDM4E 3301/4885LMNA 2914/4885RECQL 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.